AIDS-associated mycoplasmas and antibiotic susceptibilities.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

AIDS-associated mycoplasmas and antibiotic susceptibilities.

Abstr Gen Meet Am Soc Microbiol. 1993;93:166 (abstract no. G-21). Unique Identifier : AIDSLINE ASM93/93291794
Poulin SA; Perkins RE; Kundsin RB; Brigham and Women's Hospital, Boston, MA.

Abstract: Because mycoplasmas may be a cofactor in the progression of HIV infection to AIDS, their susceptibilities to antibiotics need to be understood for appropriate therapy. The mycoplasmas studied were: Mycoplasma penetrans; Mycoplasma fermentans, var. incognitus; two strains of Mycoplasma fermentans isolated from AIDS patients; Mycoplasma fermentans; and Mycoplasma pirum (both obtained from NIH). The antibiotics tested were: Clarithromycin, Azithromycin, Erythromycin, Ofloxacin, Clindamycin, Doxycycline and Tetracycline. Minimal inhibitory concentration (MIC) against Clarithromycin was also done. Using the metabolic inhibition method, all six mycoplasma strains were susceptible to Clarithromycin, Azithromycin, Ofloxacin, Clindamycin, Doxycycline and Tetracycline. M. penetrans was susceptible to Erythromycin. The M. fermentans strains and M. pirum were resistant to Erythromycin. All five mycoplasma isolates tested showed low MIC levels to Clarithromycin. The range was from < 0.125 mcg/ml--1.0 mcg/ml with a median final MIC of 0.5 mcg/ml. These tests indicate that Clarithromycin is effective and has the potential to be added to the commonly used antibiotics in the treatment of AIDS-related mycoplasmas.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/MICROBIOLOGY Antibiotics/*PHARMACOLOGY Clarithromycin/*PHARMACOLOGY Comparative Study Human HIV Infections/*COMPLICATIONS *Microbial Sensitivity Tests Mycoplasma/*DRUG EFFECTS/ISOLATION & PURIF Mycoplasma fermentans/DRUG EFFECTS/ISOLATION & PURIF Mycoplasma Infections/*COMPLICATIONS/MICROBIOLOGY ABSTRACT
930930
M9391177

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .